Dingfeng Li

Dingfeng Li

Auto-generated profile, based on publicly available information

Dingfeng Li

Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic , Rochester, MN 55905 , United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
DLDingfeng Li
Dingfeng Li
RKRavinder Jeet Kaur
Ravinder Jeet Kaur
CZCatherine D Zhang
Catherine D Zhang
AEAndreas Ebbehoj
Andreas Ebbehoj
SSSumitabh Singh
Sumitabh Singh
IBIrina Bancos
Irina Bancos
Objective: Several small studies reported increased prevalence and incidence of asymptomatic vertebral fractures in patients with non-functioning adrenal adenomas and adenomas with mild autonomous cortisol secretion. However, the risk of symptomatic fractures at vertebrae, and at other sites remains unknown. Our objective was to determine the prevalence and incidence of symptomatic site-specific fractures in patients with adrenal adenomas. Design: Population-based cohort study, Olmsted County, Minnesota, USA, 1995–2017. Methods: Participants were the patients with adrenal adenoma and age/sex-matched referent subjects. Patients with overt hormone excess were excluded. Main outcomes measures were prevalence and incidence of bone fractures. Results: Of 1004 patients with adrenal adenomas, 582 (58%) were women, and median age at diagnosis was 63 years (20–96). At the time of diagnosis, patients had a higher prevalence of previous fractures than referent subjects (any fracture: 47.9% vs 41.3%, P = 0.003, vertebral fracture: 6.4% vs 3.6%, P = 0.004, combined osteoporotic sites: 16.6% vs 13.3%, P = 0.04). Median duration of follow-up was 6.8 years (range: 0–21.9 years). After adjusting for age, sex, BMI, tobacco use, prior history of fracture, and common causes of secondary osteoporosis, patients with adenoma had hazard ratio of 1.27 (95% CI: 1.07–1.52) for developing a new fracture during follow up when compared to referent subjects. Conclusions: Patients with adrenal adenomas have higher prevalence of fractures at the time of diagnosis and increased risk to develop new fractures when compared to referent subjects.

1 December 2020 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
OKOmar El Kawkgi
Omar El Kawkgi
DLDingfeng Li
Dingfeng Li
AKAnupam Kotwal
Anupam Kotwal
RWRobert A. Wermers
Robert A. Wermers
As immune checkpoint inhibitor drugs are being used in the treatment of some cancers, unusual adverse events are being reported, labeled as immune-related adverse events. Various endocrinopathies related to immune-related adverse events have been described, among which hypoparathyroidism is exceedingly rare. We report a case of hypoparathyroidism induced by immune checkpoint drugs, highlighting the need for awareness of this emerging complication.

29 March 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DLDingfeng Li
Dingfeng Li
SBSarah Brand
Sarah Brand
OHOksana Hamidi
Oksana Hamidi
AWAshleigh A Westfall
Ashleigh A Westfall
MSMalavika Suresh
Malavika Suresh
IBIrina Bancos
Irina Bancos
Context: Current evidence on determinants of quality of life (QoL) in patients with adrenal insufficiency (AI) is limited. Objective: This work aimed to identify the determinants of QoL in different subtypes of AI. Methods: This multicenter cross-sectional survey study was conducted using a patient-centered questionnaire, the Short Form-36. Results: Of 529 participants, 223 (42.2%) had primary AI, 190 (35.9%) had secondary AI, and 116 (21.9%) had glucocorticoid-induced AI. Median age was 58 years (interquartile range: 43-68 years) and 342 (64.8%) were women. In multivariable analyses, patients were more likely to report worse physical scores if they were women (odds ratio [OR]: 3.3; 95% CI, 1.8-6.0), had secondary AI or glucocorticoid-induced AI (OR: 2.5; 95% CI, 1.4-4.3), had shorter duration of AI (OR: 2.0; 95% CI, 1.1-3.6), were treated with more than 25 mg hydrocortisone equivalent daily (OR: 2.3; 95% CI, 1.2-4.6), had more comorbidities related to glucocorticoid excess (OR: 2.3; 95% CI, 1.3-4.0), reported a higher financial burden from AI (OR: 2.1; 95% CI, 1.3-3.6), and reported difficulties with AI management (OR: 2.5; 95% CI, 1.2-5.2). Women (OR: 2.1; 95% CI, 1.08-4.0), shorter duration of AI (OR: 2.4; 95% CI, 1.4-4.3), higher financial burden (OR: 2.3; 95% CI, 1.3-4.0), difficulties with AI management (OR: 2.6; 95% CI, 1.4-4.9), and lack of family support (OR: 9.1; 95% CI, 2.3-33.3) were associated with worse mental component scores. Conclusion: In patients with AI, QoL could be improved by addressing certain determinants, such as avoiding GC overreplacement, providing in-depth education on self-management, offering more comprehensive insurance coverage, and ensuring better family support.

28 June 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
LCLindsay E. Carafone
Lindsay E. Carafone
CZCatherine D. Zhang
Catherine D. Zhang
DLDingfeng Li
Dingfeng Li
NLNatalia Lazik
Natalia Lazik
OHOksana Hamidi
Oksana Hamidi
IBIrina Bancos
Irina Bancos
Autonomous cortisol secretion (ACS) affects up to 50% of patients with adrenal adenomas. Despite the limited evidence, clinical guidelines recommend measurement of serum concentrations of dehydroepiandrosterone-sulfate (DHEA-S) and corticotropin (ACTH) to aid in the diagnosis of ACS. Our objective was to determine the accuracy of serum concentrations of DHEA-S and ACTH in diagnosing ACS. We conducted a retrospective single center study of adults with adrenal adenoma evaluated between 2000−2020. Main outcome measure was diagnostic accuracy of DHEA-S and ACTH. ACS was defined as post-dexamethasone cortisol >1.8 mcg/dL. Of 468 patients, ACS was diagnosed in 256 (55%) patients with a median post-DST cortisol of 3.45 mcg/dL (range, 1.9–32.7). Patients with ACS demonstrated lower serum concentrations of DHEA-S (35 vs. 87.3 mcg/dL, p < 0.0001) and ACTH (8.3 vs. 16 pg/mL, p < 0.0001) compared to patients with non-functioning adrenal tumors (NFAT). Serum DHEA-S concentration <40 mcg/dL diagnosed ACS with 84% specificity and 81% PPV, while serum ACTH concentration <10 pg/mL diagnosed ACS with 75% specificity and 78% PPV. The combination of serum concentrations of DHEA-S <40 mcg/dL and ACTH <10 pg/mL diagnosed ACS with the highest accuracy with 92% specificity and 87% PPV. Serum concentrations of DHEA-S and ACTH provide additional value in diagnosing ACS.

16 June 2023 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
DLDingfeng Li
Dingfeng Li
CZCatherine D Zhang
Catherine D Zhang
JSJasmine Saini
Jasmine Saini
SSSumitabh Singh
Sumitabh Singh
RNRohit Nathani
Rohit Nathani
IBIrina Bancos
Irina Bancos
Prospective data on determinants of muscle strength impairment and quality of life in patients with various subtypes and severity of endogenous hypercortisolism are lacking. Single-center cross-sectional study, 2019 to 2022. Patients with Cushing syndrome (CS) and mild autonomous cortisol secretion (MACS) were assessed with clinical and biochemical severity score, muscle function (non-dominant hand grip strength, sit-to-stand test), and quality of life(Short Form-36 [SF36] and CushingQoL). Referent subjects were recruited from the local population undergoing abdominal imaging for reasons other than suspected adrenal disorder. Of 164 patients, 81(49%) had MACS, 14(9%) had adrenal CS, 60(37%) had pituitary CS, and 9(5%) had ectopic CS. Median age was 53 years (IQR: 42-63 years), and 126 (77%) were women. SF36 mental component score was similarly low in patients with MACS vs CS, but physical component score was lower in CS when compared to MACS (mean of 34.0 vs 40.5, P = 0.001). Compared to MACS, patients with CS had lower scores on the standardized CushingQoL (mean of 47.1 v 34.2, P < 0.001). Compared to referent subjects, patients with MACS demonstrated reduced muscle strength, similar to patients with CS (mean Sit to stand Z score of -0.47 vs -0.54, P = 0.822). Clinical severity (r = -0.22, P = 0.004) but not biochemical severity was associated with sit-to-stand test performance. Both patients with overt CS and MACS demonstrate reduced muscle strength and low quality of life. The clinical severity score utilized is associated with both physical and psychosocial components of Cushing QoL and with the physical component of SF36.

27 May 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DLDingfeng Li
Dingfeng Li
MSMalavika Suresh
Malavika Suresh
TATiffany Abbondanza
Tiffany Abbondanza
AVAnand Vaidya
Anand Vaidya
IBIrina Bancos
Irina Bancos
Context The COVID-19 pandemic has impacted healthcare environment. Objective To determine the impact of the pandemic on self-reported outcomes in patients with adrenal insufficiency (AI). Design and setting Prospective longitudinal survey study at 2 tertiary centers. Participants Patients with AI. Intervention Patient-centered questionnaire. Main outcome measures Depression Anxiety Stress Scales-21, Short Form-36, and AI self-management. Results Of 342 patients, 157 (46%) had primary AI, 109 (32%) had secondary AI, and 76 (22%) had glucocorticoid-induced AI. When compared to prepandemic, daily glucocorticoid dose and number of adrenal crises did not change. However, patients reported a higher financial impact from AI (34% vs 23%, P = 0.006) and difficulty accessing medical care (31% vs 7%, P < 0.0001) during the pandemic. A third of patients reported difficulty managing AI during the pandemic. After adjusting for duration and subtypes of AI, younger patients [odds ratio (OR) 2.3, CI 95% 1.3-4.1], women (OR 3.7, CI 95% 1.9-7.1), poor healthcare access(OR 4.2, CI 95% 2.3-7.7), lack of good insurance support (OR 2.8, CI 95% 1.3-5.9), and those with a higher financial impact (OR 2.3, CI 95% 1.3-4.3) reported greater difficulties managing AI. Patients were more likely to report a higher anxiety score (≥8) if they found managing AI challenging during the pandemic (OR 3.0, CI 95% 1.3-6.9), and had lower Physical Component Summary (OR 4.9, CI 95% 2.2-11.0) and Mental Component Summary (OR 4.1, CI 95% 1.8-9.5) scores prior to the pandemic. Conclusions A third of patients with AI reported difficulties with management of AI during the pandemic, particularly in younger patients, women, and those with poor healthcare access.